b
r
c
recent
data
suggest
human
rhinoviru
hrv
associ
lower
respiratori
tract
infect
mortal
hematopoiet
cell
transplant
hct
recipi
examin
risk
factor
prolong
viral
shed
may
provid
critic
insight
develop
novel
therapeut
help
inform
infect
prevent
practic
object
identifi
risk
factor
prolong
shed
hrv
posthct
prospect
collect
weekli
nasal
sampl
allogen
hct
recipi
day
day
posttranspl
perform
realtim
revers
transcriptas
pcr
decemb
februari
subject
symptomat
hrv
infect
neg
test
within
week
last
posit
includ
durat
shed
defin
time
first
posit
first
neg
sampl
cycl
threshold
ct
valu
use
proxi
viral
load
hrv
speci
identifi
sequenc
noncod
region
logist
regress
analys
perform
evalu
factor
associ
prolong
shed
day
identifi
hct
recipi
hrv
infect
fulfil
studi
criteria
adult
children
median
durat
shed
day
x
xrang
day
patient
prolong
shed
among
sampl
sequenc
speci
speci
b
c
account
median
shed
durat
hrv
differ
among
speci
p
bivari
logist
regress
analys
suggest
initi
high
viral
load
low
ct
valu
associ
prolong
shed
hct
recipi
initi
high
viral
load
risk
prolong
hrv
viral
shed
impact
respiratori
viral
infect
hematopoiet
cell
transplant
hct
recipi
wide
appreci
human
rhinovirus
hrv
increasingli
recogn
seriou
pathogen
frequent
associ
lower
respiratori
tract
infect
mortal
prolong
shed
need
effect
antivir
therapi
popul
new
therapeut
investig
defin
risk
factor
prolong
shed
may
provid
import
inform
riskstratifi
subject
antivir
clinic
trial
viral
load
endpoint
furthermor
risk
factor
prolong
viral
shed
may
inform
effect
infect
prevent
practic
object
studi
evalu
viral
host
factor
associ
prolong
hrv
shed
upper
respiratori
tract
hct
recipi
conduct
prospect
surveil
studi
patient
undergo
allogen
hct
fred
hutchinson
cancer
research
center
decemb
februari
first
day
posttranspl
weekli
standard
respiratori
symptom
survey
viral
pcr
test
upper
respiratori
sampl
perform
subject
respiratori
symptom
time
first
hrv
detect
day
posthct
includ
current
studi
subject
includ
end
viral
shed
period
could
defin
neg
viral
pcr
test
result
occur
within
week
last
posit
test
x
x
studi
approv
institut
review
board
fred
hutchinson
cancer
research
center
hrv
rna
detect
upper
respiratori
tract
specimen
nucleic
acid
extract
realtim
revers
transcriptas
pcr
rtpcr
cycl
threshold
ct
use
invers
proxi
viral
load
lower
ct
x
x
correl
higher
viral
load
sanger
sequenc
perform
noncod
region
use
save
nasal
sampl
shed
durat
defin
time
first
posit
first
neg
sampl
prolong
shed
defin
shed
day
highest
daili
steroid
dose
lowest
cell
count
week
first
hrv
detect
record
covari
select
previous
identifi
risk
factor
prolong
shed
human
coronaviru
diseas
progress
respiratori
virus
well
import
biolog
variabl
thought
influenc
shed
durat
continu
covari
age
ct
analyz
continu
dichotom
median
variabl
univari
bivari
logist
regress
analys
perform
evalu
associ
covari
prolong
shed
variabl
p
valu
univari
model
candid
bivari
model
mannwhitney
u
kruskalw
test
perform
compar
continu
valu
group
respect
twosid
p
valu
consid
statist
signific
statist
analys
perform
use
sa
window
sa
institut
cari
nc
identifi
hct
recipi
hrv
infect
fulfil
studi
criteria
adult
children
tabl
approxim
one
half
patient
leukopen
week
x
xviru
detect
patient
receiv
highdos
steroid
mgkgday
median
durat
shed
day
x
xrang
day
patient
prolong
shed
day
among
patient
ct
valu
median
prolong
shed
among
patient
prolong
shed
progress
lower
respiratori
tract
infect
base
posit
hrv
pcr
bronchoalveolar
lavag
specimen
day
shed
period
patient
shorter
shed
progress
among
sequenc
nasal
sampl
speci
speci
b
c
median
shed
durat
differ
among
speci
p
supplementari
figur
anoth
patient
asymptomat
time
first
detect
hrv
median
initi
viral
load
patient
differ
symptomat
patient
p
among
initi
asymptomat
patient
subsequ
develop
respiratori
symptom
shed
period
time
develop
symptom
median
day
interquartil
rang
day
patient
progress
lower
respiratori
tract
infect
higher
viral
load
lower
ct
valu
onset
associ
longer
shed
durat
figur
tabl
bivari
logist
regress
analys
indic
initi
ct
median
consist
associ
prolong
shed
model
figur
similar
analys
evalu
ct
continu
variabl
show
consist
result
except
number
transplant
statist
signific
data
shown
nonmyeloabl
condit
associ
prolong
shed
howev
longer
statist
signific
adjust
age
transplant
number
transplant
data
present
n
median
x
x
rang
week
first
rhinoviru
detect
cohort
allogen
hct
recipi
prospect
upper
respiratori
tract
sampl
initi
high
viral
load
associ
prolong
shed
hrv
shed
durat
appear
similar
across
hrv
speci
widespread
use
molecular
diagnost
hrv
increasingli
report
seriou
pathogen
immunocompromis
host
hrv
demonstr
common
lower
respiratori
tract
mortal
lower
respiratori
tract
infect
compar
seen
wellestablish
respiratori
pathogen
includ
respiratori
syncyti
viru
parainfluenza
viru
influenza
among
respiratori
virus
hrv
prone
shed
long
period
transplant
recipi
prolong
viral
shed
potenti
contribut
hrv
transmiss
particular
concern
infect
prevent
although
hospit
outbreak
mainli
report
respiratori
virus
current
studi
patient
develop
lower
respiratori
tract
infect
period
prolong
shed
studi
larg
enough
sampl
size
analyz
effect
prolong
shed
advers
clinic
outcom
studi
need
clarifi
whether
prolong
shed
significantli
affect
clinic
outcom
grow
concern
regard
poor
outcom
associ
hrv
infect
follow
hct
led
recognit
need
antivir
agent
viral
shed
durat
often
use
endpoint
clinic
trial
new
antivir
identifi
risk
factor
prolong
shed
thu
critic
appropri
stratif
patient
random
trial
howev
data
factor
associ
prolong
shed
respiratori
virus
limit
except
influenza
viru
mainli
immunocompet
popul
coronaviru
hct
recipi
present
studi
show
initi
high
viral
load
risk
factor
prolong
hrv
shed
hct
recipi
consist
previou
studi
coronaviru
studi
somewhat
unexpectedli
show
nonmyeloabl
condit
associ
prolong
shed
adjust
viral
load
hypothes
associ
partli
due
nonmyeloabl
condit
common
older
patient
undergo
second
transplant
group
like
prolong
shed
condit
regimen
statist
signific
adjust
factor
limit
studi
rel
small
sampl
size
allow
us
perform
bivari
logist
regress
analys
howev
associ
x
xbetween
initi
viral
load
prolong
shed
appear
robust
shown
consist
differ
model
abl
perform
sequenc
twothird
patient
primarili
due
low
viral
load
thu
abil
detect
small
differ
shed
durat
among
hrv
speci
limit
quantif
hrv
use
rtpcr
assay
consensu
hrv
primer
probe
set
may
limit
due
divers
hrv
genotyp
revers
transcriptas
digit
pcr
shown
accur
quantif
howev
overal
perform
rtpcr
appear
similar
revers
transcriptas
digit
pcr
genotyp
low
ct
valu
dichotom
median
consist
associ
prolong
shed
model
therefor
differ
quantif
method
unlik
significantli
impact
conclus
final
defin
end
shed
first
neg
x
xviru
detect
x
xregardless
whether
patient
continu
respiratori
symptom
possibl
shed
viral
load
limit
detect
present
felt
definit
would
object
use
durat
symptom
ongo
symptom
necessarili
attribut
persist
hrv
infect
summari
initi
high
viral
load
risk
factor
prolong
shed
hrv
hct
recipi
import
find
futur
design
random
clinic
trial
novel
therapeut
viral
load
endpoint
data
may
also
inform
effect
infect
control
polici
expect
hrv
shed
durat
day
patient
high
viral
load
conflict
interest
statement
mb
receiv
research
support
unrel
research
serv
consult
aviragen
aw
receiv
research
support
aviragen
unrel
research
author
declar
compet
interest
odd
ratio
confid
interv
bivari
model
evalu
ct
valu
median
risk
factor
prolong
shed
n
supplementari
data
relat
articl
found
onlin
